Document:

Exhibit 10.28

 

THE
SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND
MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR HYPOTHECATED UNLESS (A) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT,
AND APPLICABLE STATE SECURITIES LAWS, COVERING ANY SUCH TRANSACTION INVOLVING SAID SECURITIES, (B) THE COMPANY RECEIVES AN OPINION
OF LEGAL COUNSEL FOR THE HOLDER OF THESE SECURITIES SATISFACTORY TO THE COMPANY STATING THAT SUCH TRANSACTION IS EXEMPT FROM REGISTRATION,
OR (C) THE COMPANY OTHERWISE SATISFIES ITSELF THAT SUCH TRANSACTION IS EXEMPT FROM REGISTRATION.

 

Date
of Issuance: March 16, 2020

 

WARRANT
TO PURCHASE SERIES B PREFERRED STOCK OF

 

CELULARITY
INC.

 

For
value received, Celularity Inc., a Delaware corporation (the “Company”), hereby grants to ________________
(“Holder”), this Warrant to purchase that number of shares of the Company’s Series B Preferred
Stock as set forth in Section 2(b) hereof, as may be adjusted from time to time pursuant to Section 13 hereof.

 

1. Definitions.

 

(a) “Act”
shall mean the Securities Act of 1933, as amended.

 

(b) “Business
Days” shall mean any day other than a Saturday, a Sunday or any other day on which the Federal Reserve Bank of New
York is required by Law to be closed.

 

(c) “Change
of Control” shall mean a transaction or a series of related transactions involving (i) a consolidation or merger
of the Company which results in the stockholders of the Company immediately prior to the transaction owning less than a majority
of the equity or voting power of the surviving entity, (ii) the sale, transfer or lease of all or substantially all of the Company’s
assets taken as a whole together with any assets of the Company’s subsidiaries, whether by merger, consolidation or otherwise,
and whether in a single transaction or a series of related transactions, (iii) the grant of an exclusive license to all or substantially
all of the Company’s intellectual property that is used to generate all or substantially all of the Company’s revenues,
or (iv) any sale of all or substantially all of the Company’s equity or any other transaction which results in the stockholders
of the Company immediately prior to the transaction owning less than a majority of the equity or voting power of the surviving
entity but not including any transaction or series of transactions principally for bona fide equity financing purposes in which
cash is received by the Company or indebtedness of the Company is cancelled or converted (or a combination thereof).

 

(d) “Common
Stock” shall mean the Common Stock, par value $0.0001 per share, of the Company.

 

(e) “Initial
Public Offering” means the first firm commitment underwritten public offering of securities of the Company pursuant
to an effective registration statement under the Act (other than a registration statement relating either to a sale of securities
to employees of the Company pursuant to a stock option, stock purchase or similar plan or an SEC Rule 145 transaction).

 

      

     

    

 

(f) “Investors’
Rights Agreement” means that certain Amended and Restated Investors’ Rights Agreement, dated as of March 16,
2020, by and among the Company, Holder and the other parties thereto, as amended and/or restated from time to time.

 

(g) “Restated
Certificate” shall mean the Company’s Amended and Restated Certificate of Incorporation as of the date hereof,
as amended and/or restated from time to time.

 

(h) “Series
B Preferred Stock” shall mean the Series B Preferred Stock, par value $0.0001 per share, of the
Company.

 

(i) “Stock
Purchase Agreement” shall mean that certain Series B Preferred Stock Purchase Agreement, dated as of March 16, 2020,
by and among the Company and the Investors listed on Schedule A, thereto.

 

(j) “Voting
Agreement” means that certain Amended and Restated Voting Agreement, dated as of March 16, 2020, by and among the
Company, Holder and the other parties thereto, as amended and/or restated from time to time.

 

(k) “Warrant”
as used herein shall include this warrant (as the same may be amended from time to time) and any warrants delivered in substitution
or exchange therefor as provided herein.

 

2. Exercise
Amount and Price.

 

(a) The
exercise price per share (the “Exercise Price”) at which this Warrant will be exercised shall be $______.

 

(b) This
Warrant is exercisable for the purchase of ____________ shares of Series B Preferred Stock (as such number may be adjusted from
time to time pursuant to Section 13 hereof).

 

3. Term.
Subject to the terms and conditions set forth herein, the Holder may exercise this Warrant, in whole or in part, during the term
commencing on the date hereof and ending at 5:00 p.m. (Eastern Time) on the first to occur of (a) the 60-month anniversary of
the date of issuance of this Warrant written above, (b) the consummation of the Company’s Initial Public Offering, (c) the
consummation of a Change of Control. The Company will give Holder not less than twenty (20) days’ advance written notice
of a transaction listed in Sections 3(b) through 3(c) hereof.

 

4. Exercise
of Warrant. The purchase rights represented by this Warrant are exercisable by the Holder in whole or in part, at any
time, or from time to time, during the term hereof as described in Section 3 above, by the surrender of this Warrant and the Notice
of Exercise annexed hereto duly completed and executed on behalf of the Holder, at the principal offices of the Company (or such
other office or agency of the Company as it may designate by notice in writing to the Holder), upon payment in cash or by check
acceptable to the Company of the Exercise Price of the shares to be purchased.

 

      

     

    

 

5. Representations
and Warranties of the Company. The Company hereby represents and warrants to Holder that the following representations
and warranties are true and correct:

 

(a) Organization,
Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the
laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted and
as proposed to be conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in
which the failure to so qualify would have a material adverse effect on its business or properties.

 

(b) Authorization.
All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution
and delivery of this Warrant, the performance of all obligations of the Company hereunder and thereunder, and the reservation
for issuance, sale and delivery of the Series B Preferred Stock and the shares of Common Stock to be issued upon conversion of
the Series B Preferred Stock issued in connection with the exercise of this Warrant (the “Conversion Shares”)
has been taken. This Warrant constitutes the valid and legally binding obligation of the Company, enforceable against the Company
in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other
laws of general application affecting enforcement of creditors’ rights generally, and (ii) as limited by laws relating to
the availability of specific performance, injunctive relief or other equitable remedies.

 

(c) Valid
Issuance of Preferred and Common Stock. The Series B Preferred Stock for which the Warrant is exercisable, when issued, sold and
delivered in accordance with the terms of this Warrant for the consideration expressed herein, will be duly and validly issued,
fully paid, and nonassessable, and will be free of restrictions on transfer other than restrictions on transfer under this Warrant,
the Investors’ Rights Agreement and the Voting Agreement and under applicable state and federal securities laws or liens
or encumbrances created by or imposed by Holder. The Conversion Shares have been duly and validly reserved for issuance as of
the date hereof and, upon issuance in accordance with the terms of the Restated Certificate, will be duly and validly issued,
fully paid, and nonassessable and will be free of restrictions on transfer other than restrictions on transfer under this Warrant,
the Investors’ Rights Agreement and the Voting Agreement of the Company, each as amended and restated and currently in effect,
and under applicable state and federal securities laws.

 

(d) Governmental
Consents. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing
with, any federal, state or local governmental authority on the part of the Company is required in connection with the issuance
or exercise of this Warrant, except for (i) such federal and state securities filings as may be necessary, which filings will
be timely effected after the date hereof and (ii) such other approval that has been obtained prior to the date hereof.

 

(e) Reliance
by Holder. The Company understands that the representations, warranties, covenants and acknowledgements set forth in this Section
5 constitute a material inducement to Holder entering into this Warrant.

 

6. Representations
and Warranties of Holder. Holder hereby represents and warrants to the Company that the following representations and
warranties are true and correct:

 

(a) Purchase
Entirely for Own Account. This Warrant is being entered into for investment for Holder’s own account not as a nominee
or agent, and not with a view to the resale or distribution of any part thereof, and Holder has no present intention of
selling, granting any participation in, or otherwise distributing the same. The acquisition by Holder of this Warrant shall
constitute confirmation of the representation by Holder that it does not have any contract, undertaking, agreement or
arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to
this Warrant.

 

      

     

    

 

(b) Investment
Experience. Holder is an investor in securities of companies in the development stage and acknowledges that it is able to fend
for itself, can bear the economic risk of its investment, and has such knowledge and experience in financial or business matters
that it is capable of evaluating the merits and risks of entering into this Warrant. Holder acknowledges that the acquisition
of shares of Series B Preferred Stock pursuant to this Warrant involves a high degree of risk, and represents that it is able,
without materially impairing its financial condition, to hold such shares for an indefinite period of time and to suffer a complete
loss of its investment. Holder acknowledges that the Company has not made any representations or warranties as to whether the
Exercise Price to be paid by Holder for the Series B Preferred Stock is a fair value for such shares and the Company takes no
position with respect to the fairness of the Exercise Price or the future prospects and valuation of the Company. Holder is aware
of the fact that the value of the Series B Preferred Stock to be purchased upon exercise of this Warrant may significantly depreciate
over time and there can be no assurances that the value of such shares will increase or to what extent. In connection with making
an investment decision in connection with entering into this Warrant, Holder will be relying on its own knowledge and experience
and advice obtained from Holder’s legal, tax and financial advisor

 

(c) Accredited
Investor. Holder is an “accredited investor” within the meaning of SEC Rule 501 of Regulation D, as presently in effect.

 

(d) Restricted
Securities. Holder understands that this Warrant, as well as the Series B Preferred Stock to be purchased upon exercise hereof,
are and will be characterized as “restricted securities” under the federal securities laws inasmuch as they are and
will be acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations
such securities may be resold without registration under the Act only in certain limited circumstances. In this connection, Holder
represents that it is familiar with SEC Rule 144, as presently in effect, and understands the resale limitations imposed thereby
and by the Act. HOLDER UNDERSTANDS AND ACKNOWLEDGES HEREIN THAT AN INVESTMENT IN THE COMPANY’S SECURITIES INVOLVES AN EXTREMELY
HIGH DEGREE OF RISK AND MAY RESULT IN A COMPLETE LOSS OF ITS INVESTMENT. Holder understands that neither this Warrant nor the
shares of Series B Preferred Stock to be purchased upon exercise of this Warrant have been or will be registered under the Act
and have not been and will not be registered or qualified in any state in which they are offered, and thus the Holder will not
be able to resell or otherwise transfer this Warrant or the shares of Series B Preferred Stock issued upon exercise of this Warrant
unless they are registered under the Act and registered or qualified under applicable state securities laws, or an exemption from
such registration or qualification is available. Holder has no immediate need for liquidity in connection with this investment,
and does not anticipate that Holder will be required to sell this Warrant or the shares of Series B Preferred Stock issued upon
exercise of this Warrant in the foreseeable future.

 

      

     

    

 

(e) Legends.
It is understood that the certificates, if any, evidencing the shares of Series B Preferred Stock issuable upon exercise of this
Warrant may bear one or all of the following legends, in addition to any other legends that may be set forth in agreements to
which the Holder is a party:

 

(i) “THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE,
PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR
AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO RULE 144
OF SUCH ACT.”

 

(ii) Any
legend required by applicable state securities laws.

 

(f) Reliance
by Company. Holder understands that the representations, warranties, covenants and acknowledgements set forth in this Section
6 constitute a material inducement to the Company entering into this Warrant.

 

(g) Foreign
Investors. Holder hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in
connection with entering into this Warrant, including (i) the legal requirements within its jurisdiction for entering into this
Warrant and the exercise of this Warrant,

(ii)
any foreign exchange restrictions applicable to the exercise of this Warrant, (iii) any governmental or other consents that may
need to be obtained, including with respect to the payment of the Exercise Price at the applicable Closing, and (iv) the income
tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or transfer of this Warrant
or the shares of Series B Preferred Stock issuable upon exercise hereof. The Holder’s acquisition of this Warrant and payment
for the Series B Preferred Stock upon exercise of this Warrant and continued beneficial ownership of such shares will not violate
any applicable securities or other laws of the Holder’s jurisdiction.

 

7. No
Fractional Shares. No fractional share of any class or series of the Company’s capital stock shall be issued upon
exercise of this Warrant.

 

8. Replacement
of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction, or mutilation
of this Warrant and (a) in the case of loss, theft, or destruction, on delivery of an indemnity agreement reasonably satisfactory
in form and substance to the Company or (b) in the case of mutilation, on surrender and cancellation of this Warrant, the Company
shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor and amount. The Holder shall reimburse the Company
for all reasonable expenses incidental to replacement of this Warrant.

 

9. Rights
of Stockholder. This Warrant shall not entitle its holder to any of the rights of a stockholder of the Company until this
Warrant shall have been exercised and the shares of Series B Preferred Stock purchasable upon the exercise hereof shall have been
issued.

 

10. Warrant
Not Transferable. This Warrant and the rights hereunder are not transferable and/or assignable, in whole or in part, by
any party without the consent of the other party. Any transferee of the Holder, if not already a party thereto, shall, promptly
following such transfer or assignment, deliver the duly signed joinders to the Company’s then-effective Investors’
Rights Agreement and Voting Agreement. Any purported assignment in violation of this Warrant shall be void. Notwithstanding the
foregoing, Holder may not transfer this Warrant to any person or entity that the Company, in its reasonable discretion, determines
to be a competitor of the Company.

 

      

     

    

 

11. Notice
of Certain Events. Whenever the Exercise Price or number of shares purchasable hereunder shall be adjusted pursuant to
Section 13 hereof and if so requested by Holder, the Company shall issue a certificate signed by its Chief Financial Officer,
or other similar officer, setting forth in reasonable detail the event requiring the adjustment, the amount of the adjustment,
the method by which such adjustment was calculated and the Exercise Price and number of shares purchasable hereunder after giving
effect to such adjustment and shall cause a copy of such certificate to be mailed (by first class mail, postage prepaid) to the
Holder of this Warrant.

 

12. Amendments;
Waivers.

 

(a) The
provisions of this Warrant may be amended (either generally or in a particular instance and either retroactively or prospectively),
only by an instrument in writing signed by the Company and the holders of warrants to acquire at least a majority of the aggregate
shares of capital stock then issuable upon exercise of all [Holder] Warrants (as defined in the Stock Purchase Agreement);
provided, however, that any such amendment that materially and adversely affects the Holder in a manner different from
the other holders of [Holder] Warrants shall require the separate consent of the Holder hereof. In addition, subject to
the proviso in the preceding sentence, Holder agrees that such Holder’s rights hereunder may be waived or amended by persons
or entities holding [Holder] Warrants to acquire at least a majority of the aggregate shares of capital stock issuable
upon exercise of all [Holder] Warrants without obtaining any additional consents of the Holder. The foregoing shall not
limit or otherwise affect Holder’s right to waive any of such Holder’s rights hereunder with respect to itself without
obtaining the consent of any other holder of the Series B Warrants. Any amendment or waiver effected in accordance with this Section
12(a) shall be binding upon Holder and Holder’s successors and assigns.

 

(b) No
waivers of or exceptions to any term, condition or provision of this Warrant, in any one or more instances, shall be deemed to
be or construed as a further or continuing waiver of any such term, condition or provision.

 

13. Adjustments. The
Exercise Price and the number and type of shares purchasable hereunder are subject to adjustment from time to time as follows:

 

(a) Conversion
of Preferred Stock. Should prior to the expiration of this Warrant, all of the Company’s Series B Preferred Stock be, or
if outstanding would be, converted into shares of the Company’s Common Stock in accordance with the Restated Certificate,
then this Warrant shall immediately become exercisable for that number of shares of the Common Stock which would have been received
if this Warrant had been exercised in full and the Series B Preferred Stock received thereupon had been simultaneously converted
immediately prior to such event, and the Exercise Price shall be immediately adjusted to equal the quotient obtained by dividing
(i) the aggregate Exercise Price of the maximum number of shares of the Series B Preferred Stock for which this Warrant was exercisable
immediately prior to such conversion, by (ii) the number of shares of Common Stock for which this Warrant is exercisable immediately
after such conversion.

 

(b) Reclassification,
etc. If, at any time on or after the date hereof and while this Warrant remains outstanding and unexpired, the Company shall,
by reclassification of securities or otherwise, change any of the securities as to which purchase rights under this Warrant
exist into the same or a different number of securities of any other class or classes, this Warrant shall thereafter
represent the right to acquire such number and kind of securities as would have been issuable as the result of such change
with respect to the securities which were subject to the purchase rights under this Warrant immediately prior to such
reclassification or other change and the Exercise Price therefor shall be appropriately adjusted, all subject to further
adjustment as provided in this Section 13; provided, however, that the aggregate Exercise Price shall
remain the same.

 

      

     

    

 

(c) Split,
Subdivision or Combination of Shares. If at any time on or after the date hereof and while this Warrant remains outstanding and
unexpired, the Company shall split, subdivide or combine the securities as to which purchase rights under this Warrant exist into
a different number of securities of the same class, the Exercise Price for such securities shall be proportionately decreased
in the case of a split or subdivision or proportionately increased in the case of a combination. Upon an adjustment in the Exercise
Price pursuant to this Section 13(c), the number of shares subject to this Warrant (which were the subject of such split, subdivision
or combination) shall be adjusted accordingly such that the aggregate Exercise Price payable for the purchase of such shares shall
remain the same as before such split, subdivision or combination.

 

(d) Adjustments
for Dividends in Stock or Other Securities or Property. If at any time on or after the date hereof and while this Warrant remains
outstanding and unexpired, the holders of the securities as to which purchase rights under this Warrant exist at the time shall
have received, or on or after the record date fixed for the determination of eligible stockholders shall have become entitled
to receive, without payment therefor, other or additional stock or other securities or property (other than cash) of the Company
by way of dividend or other distribution in respect of the Series B Preferred Stock, then, and in each case, this Warrant shall
represent the right to acquire, in addition to the number of shares of the security receivable upon exercise of this Warrant and
without payment of any additional consideration therefor, the amount of such other or additional stock or other securities or
property (other than cash) of the Company which such holder would hold on the date of such exercise had it been the holder of
record of the security receivable upon exercise of this Warrant on the date hereof and had thereafter, during the period from
the date hereof to and including the date of such exercise, retained such shares and/or all other additional stock available by
it as aforesaid during such period, giving effect to all adjustments called for during such period by the provisions of this Section
13, and, from and after the date of such distribution, the Company shall hold and set aside (or cause to be held and set aside
in a commercially reasonable manner) an amount of such property equal to Holder’s pro rata portion thereof for distribution
to Holder pursuant hereto.

 

14. Reservation
of Capital Stock. The Company hereby covenants that at all times following the date hereof there shall be reserved for
issuance and delivery upon exercise of this Warrant such number of shares of Series B Preferred Stock as are from time to time
issuable upon exercise of this Warrant and such number of the shares of Common Stock as are from time to time issuable upon conversion
of the shares of Series B Preferred Stock which are subject to this Warrant.

 

15. Miscellaneous.

 

(a) Survival
of Representations, Warranties and Covenants. The warranties, representations and covenants of each party hereto contained in
or made pursuant to this Warrant shall survive the execution and delivery of this Warrant and shall in no way be affected by any
investigation of the subject matter thereof made by or on behalf of the Holder or the Company, as applicable.

 

      

     

    

 

(b) Titles
and Subtitles. The titles and subtitles used in this Warrant are used for convenience only and are not to be considered in construing
or interpreting this Warrant.

 

(c) Governing
Law. This Warrant is to be construed in accordance with and governed by the internal laws of the State of Delaware without giving
effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws
of the State of Delaware to the rights and duties of the parties. All disputes and controversies arising out of or in connection
with this Warrant shall be resolved exclusively by the state or federal courts located within the City of Wilmington in the State
of Delaware, and each party hereto agrees to submit to the jurisdiction of said courts and agrees that venue shall lie exclusively
with such courts.

 

(d) Waiver
of Right to Jury Trial. EACH OF HOLDER AND THE COMPANY, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY IRREVOCABLY
WAIVES ALL RIGHT TO TRIAL BY JURY AS TO ANY ISSUE RELATING HERETO IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR
RELATING TO THIS WARRANT.

 

(e) Notices.
Except as may be otherwise provided herein, all notices, requests, waivers and other communications made pursuant to this Warrant
shall be in writing and shall be conclusively deemed to have been duly given (i) when hand delivered to the other party; (ii)
when sent by email or facsimile if sent between 8:00 a.m. and 5:00 p.m. recipient’s local time on a business day, or on
the next business day if sent by email or facsimile other than between 8:00 a.m. and 5:00 p.m. recipient’s local time on
a business day; (iii) seven business days after deposit in the U.S. mail with first class or certified mail receipt requested
postage prepaid and addressed to the other party; or (iv) the next business day after deposit with an international overnight
delivery service, postage prepaid, addressed to the parties with next business day delivery guaranteed, provided that the sending
party receives a confirmation of delivery from the delivery service provider. Each person making a communication hereunder by
email or facsimile shall promptly confirm by telephone between 8:00 a.m. and 5:00 p.m. recipient’s local time on a business
day to the person to whom such communication was addressed each communication made by it by email or facsimile pursuant hereto
but the absence of such confirmation shall not affect the validity of any such communication. All communications shall be sent
to the address, email address or facsimile number of a party appearing in its signature block hereto or at such address, email
address or facsimile number as such party may designate by ten (10) days advance written notice to the other parties hereto.

 

(f) Specific
Performance. Each party hereto acknowledges and agrees that any breach of this Warrant would result in substantial harm to the
other party hereto for which monetary damages alone could not adequately compensate. Therefore, the parties hereto unconditionally
and irrevocably agree that any non-breaching party hereto shall be entitled to seek protective orders, injunctive relief and other
remedies available at law or in equity (including, without limitation, seeking specific performance).

 

(g) Counterparts.
This Warrant may be executed and delivered by facsimile signature and in two or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile,
electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g. www.docusign.com)
or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid
and effective for all purposes.

 

[Remainder
of Page Intentionally Left Blank]

 

      

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its duly authorized officer as of the Date of Issuance
indicated above.

 

	

         
	CELULARITY INC.
	 	a Delaware corporation
	 	 	 
	 	By:
     	 
	 	 	Name:   	Robert J. Hariri, M.D., Ph.D.
	 	 	Title: 	Founder, CEO and President

 

	 	Address: 	33
    Technology Drive South
	 	 	Warren,
    New Jersey 07059

 

      

     

    

 

ACKNOWLIDGED
AND AGREED:

 

	 	HOLDER:
	 	 	 
	 	By:
    	     
	 	 	 
	 	Name:
    	 
	 	 	 
	 	Title:
    	 

 

[Signature
Page to Warrant]

 

      

     

    

 

NOTICE
OF EXERCISE

 

 

		To:	Celularity
Inc.

33
Technology Drive

Warren, New Jersey 07059

 

The
undersigned (“Holder”), pursuant to the provisions set forth in the Warrant to Purchase Series B Preferred
Stock dated March 16, 2020 (the “Warrant”) hereby elects to purchase  _________________________ 
shares of the Series B Preferred Stock (as defined in the Warrant) pursuant to the terms of the Warrant, and tenders herewith
payment of the purchase price for such shares in full.

 

	 	[Print
    Name]
	 	 
	 	 
	[Date]	[Signature]Exhibit 10.29

 

Amendment
No. 1 to Warrant to Purchase Series B Preferred Stock of

Celularity Inc.

 

This
Amendment No. 1 to Warrant to Purchase Series B Preferred Stock of Celularity Inc. (this
“Amendment”) is made effective as of January 8, 2021, by and between Celularity Inc., a Delaware
corporation (the “Company”), and Starr International Investments, Ltd. (the
“Holder”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed
to them in the Warrant (as defined below).

 

Whereas,
the Company previously issued to the Holder that certain Warrant to Purchase Series B Preferred Stock of Celularity Inc. dated
as of March 16, 2020 (the “Warrant”), to purchase up to 4,320,027 shares of the Company’s Series
B Preferred Stock, $0.0001 par value per share (the “Series B Preferred Stock”);

 

Whereas,
pursuant to Section 12(a) of the Warrant, the Warrant may be modified or amended with the written consent of the Company
and the holders (the “Starr Holders”) of warrants to acquire at least a majority of the aggregate shares
of capital stock then issuable upon exercise of all Starr Warrants (the “Starr Shares”);

 

Whereas,
the Company and the Holder hereby agree to modify and amend the Warrant as described below; and

 

Whereas,
concurrently with the execution and delivery of this Amendment, the Company and each other Starr Holder have agreed to modify
and amend each Starr Warrant other than the Warrant in the same way as the Warrant is being amended pursuant to this Amendment.

 

Now,
Therefore, in consideration of the premises
and of the mutual covenants herein and for other valuable consideration, the Company and the Holder hereby agree as follows:

 

1. Section
4 of the Warrant is hereby amended and restated in its entirety to read as follows:

 

“4Exercise
of Warrant.

 

(a) The
purchase rights represented by this Warrant are exercisable by the Holder in whole or in part, at any time, or from time to time,
during the term hereof as described in Section 3 above, by the surrender of this Warrant and the Notice of Exercise annexed
hereto duly completed and executed on behalf of the Holder, at the principal offices of the Company (or such other office or agency
of the Company as it may designate by notice in writing to the Holder), upon payment in cash or by check acceptable to the Company
of the Exercise Price of the shares to be purchased (the “Shares”).

 

    1

     

    

 

(b) From
time to time following the completion of the first Trading Day immediately following, and subject to, the closing (“Closing”)
of the transactions contemplated by that certain Merger Agreement and Plan of Reorganization dated on the date hereof (without
giving effect to any amendment, modification or waiver thereof following the date hereof, the “GX Merger Agreement”),
by and among GX Acquisition Corp. (“GX”), Alpha First Merger Sub, Inc., Alpha Second Merger Sub, LLC
and the Company, in lieu of payment of the aggregate Exercise Price in the manner as specified in Section 4(a), but otherwise
in accordance with the requirements of Section 4(a), the Holder may elect to receive the Shares equal to the value of this
Warrant, or portion hereof as to which this Warrant is being exercised. Upon such exercise pursuant to this Section 4(b),
the Holder shall be issued such number of fully paid and non-assessable Shares as are computed using the following formula:

 

X
= Y(A-B)/A

 

where:

 

		X
                                         =	the
                                         number of Shares to be issued to the Holder;

 

		Y
                                         =	the
                                         number of Shares with respect to which this Warrant is being exercised;

 

		A
                                         =	the
                                         VWAP on the Trading Date immediately preceding the date of the applicable Notice of Exercise;
                                         and

 

		B
                                         =	the
                                         Exercise Price.

 

“Trading
Day” means a day on which the principal Trading Market is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the GX Class A Common Stock is listed or quoted
for trading on the date in question: the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the
NYSE American or the New York Stock Exchange (or any successors to any of the foregoing).

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (i) if the GX Class A Common Stock
is then listed or quoted on a Trading Market, the daily volume weighted average price of the GX Class A Common Stock for such
date (or the nearest preceding date) on the Trading Market on which the GX Class A Common Stock is then listed or quoted as reported
by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)); (ii) if the
GX Class A Common Stock is not then listed or quoted on a Trading Market, but is listed or quoted on OTCQB or OTCQX, the volume
weighted average price of the GX Class A Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX, as applicable;
(iii) if the GX Class A Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the GX Class
A Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the GX Class A Common Stock so reported; or (iv) in all other cases, the fair
market value of a share of GX Class A Common Stock as determined by an independent appraiser selected in good faith by the holders
of a majority in interest of the Starr Shares then outstanding and reasonably acceptable to GX.

 

For
the avoidance of doubt, if the Closing does not occur, the Warrant shall not be exercisable under this Section 4(b).

 

    2

     

    

 

2. Section
13(a) of the Warrant is hereby amended by adding the following sentence at the end of such provision:

 

“Subject
to and upon consummation of the Closing (as defined in the GX Merger Agreement), if this Warrant is not exercised in whole prior
to the Closing, this Warrant (or the unexercised portion thereof) shall be deemed to be a Converted Warrant (as defined in the
GX Merger Agreement), with the rights set forth in Section 3.01(b)(iv) of the GX Merger Agreement.”

 

3. The
form of Notice of Exercise attached to the Warrant is hereby amended and restated in its entirety by the form attached hereto
as Exhibit A.

 

4. This
Amendment may be executed and delivered in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including
pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission
method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for
all purposes.

 

5. This
Amendment is to be construed in accordance with and governed by the internal laws of the State of Delaware without giving effect
to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the
State of Delaware to the rights and duties of the parties. All disputes and controversies arising out of or in connection with
this Amendment shall be resolved exclusively by the state or federal courts located within the City of Wilmington in the State
of Delaware, and each party hereto agrees to submit to the jurisdiction of said courts and agrees that venue shall lie exclusively
with such courts.

 

6. Except
as expressly amended and modified hereby, the Warrant shall remain in full force and effect, and shall be binding on all parties
thereto, and the Warrant shall be read together and construed with this Amendment.

 

[Signature
Page to Follow]

 

    3

     

    

 

IN
WITNESS WHEREOF, the parties have caused this Amendment to be duly executed as of the day and year first written above.

 

	 	COMPANY:
	 	 	 	 
	 	CELULARITY INC.
	 	 	 	 
	 	By:	/s/ Robert J. Hariri
	 	 	Name:  	Robert J. Hariri, M.D., Ph.D.
	 	 	Title:	Chief Executive Officer
	 	 	 	 
	 	HOLDER:
	 	 	 	 
	 	STARR INTERNATIONAL INVESTMENTS, LTD.
	 	 	 	 
	 	By:	/s/ John J. Casale
	 	 	Name:	John J. Casale
	 	 	Title:	Authorized Signatory

 

    4

     

    

 

Exhibit
A

 

Notice
of Exercise

 

	To:	Celularity
Inc.
	 	170
Park Avenue
	 	Florham
Park, NJ 07932

 

By
checking the appropriate line, the undersigned (“Holder”), pursuant to the provisions set forth in the
Warrant to Purchase Series B Preferred Stock dated March 16, 2020, as amended (the “Warrant”), hereby
elects to purchase ____________ shares of [Series B Preferred Stock] / [GX Class A Common Stock] (as defined in the Warrant) pursuant
to the terms of the Warrant, and tenders herewith payment of the purchase price for such shares in full as follows:

 

		☐	check
in the amount of $________ payable to order of the Company enclosed herewith

 

		☐	wire
transfer of immediately available funds to the Company’s bank account

 

		☐	cashless
exercise pursuant to Section 4(b) of the Warrant

 

	

         
	 	 
	 	 	[Print
    Name]
	 	 	 
	 	 	 	
	[Date]	 	[Signature]

 

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]